Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
09:07am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene mo
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
08:30am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Joel Greenblatt's Strategic Moves: A Closer Look at State Street SPDR S&P 500 ETF Trust
02:01pm, Wednesday, 18'th Feb 2026
Insights from the Fourth Quarter 2025 13F Filing Joel Greenblatt (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providin
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Wednesday, 18'th Feb 2026
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Public Sector Pension Investment Board Purchases Shares of 381,172 Sarepta Therapeutics, Inc. $SRPT
04:04am, Wednesday, 18'th Feb 2026
Public Sector Pension Investment Board acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the undefined quarter, according to the company in its most recent Form 13F filing
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
08:30am, Wednesday, 11'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results
Head to Head Survey: Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT)
04:44am, Tuesday, 10'th Feb 2026
Edgewise Therapeutics (NASDAQ: EWTX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two co
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Brokerages
02:37am, Thursday, 05'th Feb 2026
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight brokerages that are presently covering the stock, Marketbeat.com rep
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
08:30am, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Med
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags
04:38am, Sunday, 01'st Feb 2026
Sarepta Therapeutics (NASDAQ: SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ELEVIDYS, highlighting what executives described as the first large, well-cont
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
11:50am, Tuesday, 27'th Jan 2026
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 26'th Jan 2026
Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
10:40am, Monday, 26'th Jan 2026
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDY
Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys
08:53am, Monday, 26'th Jan 2026
Sarepta reports positive, statistically significant results in a study evaluating the efficacy of its blockbuster gene therapy.
